AJ Vaccines brings in former Lundbeck exec as new CEO

At the end of January, Jesper Helmuth Larsen left AJ Vaccines, which he had led since 2019. Former Lundbeck and Otsuka exec Ole Vahlgren is now picking up the CEO mantle.

After two years at the helm, Jesper Helmuth Larsen has decided to step down from his CEO position as AJ Vaccines | Photo: Jan Bjarke Mindegaard / Watch Medier

On February 1, a ”change of guards” is taking place at AJ Vaccines, as the company puts it in a press release. Jesper Helmuth Larsen is stepping down as CEO and Ole Vahlgren is taking over the reins.

Helmuth Larsen first joined AJ Vaccines as CFO but was promoted to the top position in 2019. He succeeded Klaus Hermansen, who had spearheaded the company since it was founded in 2017 when the life science division of the Aljomaih Group of Saudi Arabia, AJ Biologics, acquired the vaccine production unit of the Danish State Serum Institute (SSI), which had been for sale for three years at the time.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs